China Drug Development Trends – Pipeline Drugs, Key Players and Deals
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Reasons to buy the ‘China Drug Development Trends’ report:
- Study objectives of the report.
- Analyze China’s drug development activities, including the most promising agents.
- Explore the growth of CAR-T cell and ADC therapies in this market.
- Examine the role of China’s regulatory environment in accelerating the approval of innovative therapies.
- Assess the growth in clinical trials conducted in China.
- Analyze deal-making activity trends.
- Report design.
How is our ‘China Drug Development Trends’ report unique from other reports in the market?
- Gain insights into China’s rapidly evolving drug development landscape, including key innovative therapies.
- Understand the growth trajectory and market potential of CAR-T cell and ADC therapies in China.
- Explore the impact of China’s regulatory reforms on the accelerated approval.
- Stay informed on the increasing number of clinical trials conducted in China.
- Identify emerging trends in deal-making activities and partnership opportunities.
We recommend this valuable source of information to anyone involved in:
- Drug Development and Pharma/Biotech Companies – Value Chain
- Pharmaceutical Industry Suppliers and Distributors
- Pharma/Drug Manufacturing Companies – Leaders and Startups
- Business Development and Market Intelligence
- Investment Analysts and Portfolio Managers
- Professional Services – Investment Banks, PE/VC Firms
- M&A/Investment, Management Consultants, and Consulting Firms
To Get a Snapshot of the China Drug Development Trends Report
China Drug Development Trends Report Overview
China’s drug development market has grown at a CAGR of more than 18% in 2024. Robust innovation has driven China to emerge as a critical player in global drug development. The pharmaceutical industry in the country has seen a surge in drug development activities in recent years, with an increasing focus on innovative therapies such as CAR-T cell and ADC therapies. This growth is also bolstered by a supportive regulatory environment that encourages innovation and expedites drug approvals. Alongside these developments, the number of clinical trials conducted within China has risen significantly and deal-making has intensified, further solidifying the country’s role in the global pharmaceutical landscape.
China drug development trends report explores the key metrics shaping the sector, including approved and pipeline drugs, and deal-making trends to assess its impact on the global pharmaceutical industry.
Buy the Full Report for More Insights into China’s Drug Development Trends, Download a Free Report Sample
| Key Technology Areas | · CAR-T
· ADC · mRNA · siRNA · TCR |
| Key Deal Types | · Venture Financing
· Contract Service Agreement · Partnership · Licensing Agreement · Equity Offering |
| Key Competitors | · Jiangsu Hengrui Medicine Co Ltd
· CSPC Pharmaceutical Group Ltd · Simcere Pharmaceutical Group Ltd · Innovent Biologics Inc · Qilu Pharmaceutical Co Ltd |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
China Drug Development Trends - Technology Areas
A few of the key technology areas in the China drug development market are CAR-T, ADC, mRNA, siRNA, and TCR among others. The primary technology areas being explored by Chinese companies are CAR-T therapies. Currently, there are a significant number of oligonucleotide-based treatment modalities in development, with a prominent proportion focused on small interfering RNA (siRNA) therapies.
China Drug Development Market Analysis by Technology Area
Buy the Full Report for More Technology Area Insights into China’s Drug Development Trends, Download a Free Report Sample
China Drug Development Trends – Deal Type
A few of the key deal types in the China drug development market are venture financing, contract service agreement, partnership, licensing agreement, and equity offering, among others. Venture financing is the predominant deal type in the market. Contract service agreement also had a significant share in the market.
China Drug Development Market Analysis by Deal Type
Buy the Full Report for More Deal Type Insights into China’s Drug Development Trends, Download a Free Report Sample
China Drug Development Trends – Competitive Landscape
The major competitors in the China drug development market are Jiangsu Hengrui Medicine, CSPC Pharmaceutical Group, Simcere Pharmaceutical Group, Innovent Biologics Inc, and Qilu Pharmaceutical Co Ltd, among others. Approximately 50% of the pipeline assets for these companies are in late-stage clinical trials (Phases II and later). Jiangsu Hengrui Medicine has a significant number of drugs in the pre-registration stage and in the clinical stages.
China Drug Development Market Analysis by Deal Type
Buy the Full Report for More Competitor Insights into China’s Drug Development Trends, Download a Free Report Sample
China Drug Development Trends
- Venture Financing
- Contract Service Agreement
- Partnership
- Licensing Agreement
- Equity Offering
Table of Contents
Frequently asked questions
-
Which is the leading technology area in the China drug development market?
The leading technology area in the China drug development market is CAR-T therapies.
-
Which is the leading deal type in the China drug development market?
The leading deal type in the China drug development industry is venture financing.
-
Which are the key companies in the China drug development market?
The major competitors in the China drug development market are Jiangsu Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Ltd, Simcere Pharmaceutical Group Ltd, Innovent Biologics Inc, and Qilu Pharmaceutical Co Ltd among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Drug Manufacturers reports


